

Cangene Corporation

[View the current Cangene Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/20404-Cangene+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/20404-Cangene+Corporation.html>)

Contact Details:

155 innovation Drive

Winnipeg

Manitoba

R3T 5Y3

Canada

Tel: (204) 275-4178

Fax: (204) 269-7003

Email: sales@cangene.com

Cangene is a world leader in the development, manufacture, and commercialization of specialty hyperimmune plasma and biotechnology products. Cangene has built two decades of success with the life-antibody products, such as WinRho®SDF. We are the leader in the fight against infectious diseases such as smallpox, hepatitis B, and anthrax.

Recent Publications by Cangene Corporation:



- [Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.](#)
*Plasma products for therapeutic use pose specific challenges in...*5th November, 2008
Product Development, Cangene Corporation, Winnipeg, Manitoba, Canada.- *Am J Ther.* 2008 Sep-Oct;15(5):435-43. ([DOI Direct Link](#))
- [Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin.](#)
*To compare the pharmacokinetics, safety, and tolerability of the liquid...*15th October, 2008
Cangene Corporation, Medical Affairs, 155 Innovation Drive, Winnipeg,- *Biologicals.* 2008 Jul;36(4):256-62. Epub 2008 Apr 10. ([DOI Direct Link](#))
- [Preparation and characterization of monopegylated human granulocyte-macrophage colony-stimulating factor.](#)
*ABSTRACT Conjugates of recombinant human granulocyte-macrophage...*15th April, 2008
Cangene Corporation, Mississauga, ON, Canada M9W 6A9.- *J Interferon Cytokine Res.* 2008 Feb;28(2):101-12. ([DOI Direct Link](#))
- [Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents.](#)
*Burkholderia pseudomallei is a biothreat agent and an important natural...*4th April, 2008
Cangene Corporation, Mississauga, ON, Canada.- *FEMS Immunol Med Microbiol.* 2008

- Jan;52(1):78-87. Epub 2007 Nov 11. ([DOI Direct Link](#))
- [On the influence of vector design on antibody phage display.](#)
*Phage display technology is an established technology particularly useful...*23rd March, 2007
 Cangene Corporation, 3403 American Drive, Mississauga, Ontario L4V 1T4,- J Biotechnol. 2007 Jan 20;127(4):626-37. Epub 2006 Sep 22. ([DOI Direct Link](#))
 - [Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoprotein.](#)
*The cynomolgus macaque, Macaca fascicularis, is frequently used in...*21st January, 2006
 Cangene Corporation, 3404 American Drive, Mississauga, Ontario L4V 1T4,- Immunogenetics. 2005 Nov;57(10):730-8. Epub 2005 Nov 8. ([DOI Direct Link](#))
 - [Purification and characterization of recombinant Streptomyces griseus aminopeptidase.](#)
*Recombinant Streptomyces griseus aminopeptidase (SGAP) was produced using...*12th February, 2004
 Department of Biotechnology Research, Cangene Corporation, Mississauga,- Protein Expr Purif. 2003 Jul;30(1):62-8.
 - [A new helper phage and phagemid vector system improves viral display of antibody Fab fragments and avoids propagation of insert-less virions.](#)
*Phage display technology (PDT) is a powerful method for isolating...*10th April, 2003
 Cangene Corporation, 3403 American Drive, L4V 1T4, Mississauga, Ontario,- J Immunol Methods. 2003 Mar 1;274(1-2):233-44.

Press Releases on Cangene Corporation:

Centene Corporation to Present at Upcoming Healthcare Conferences	6th November, 2009	Centene Corporation	ST. LOUIS, Nov. 6 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that it will present at two upcoming healthcare conferences over the next few weeks. Next week, at the
Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results	6th November, 2009	BioSpecifics Technologies Corp.	-- In its September 3, 2009 edition, The New England Journal of Medicine published data from the pivotal CORD I Phase III clinical trial of XIAFLEX for the treatment of Dupuytren
"AIM"ING FOR BETTER ASTHMA CARE	6th November, 2009	Schering Corporation	Asthma Insight and Management (AIM) Survey Reveals Unmet Needs in Current Asthma Care in the United States Asthma is a chronic condition affecting more than 22 million adults and children in

[Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular\(R\) Ophthalmic Solution](#)

6th November, 2009

Caraco Pharmaceutical Laboratories, Ltd.

DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US

[Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants](#)

6th November, 2009

Myriant Technologies LLC

QUINCY, Mass., Nov. 6 /PRNewswire/ -- Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and

BioNews Results for Cangene Corporation



- [Cangene acquires U.S. commercialization rights for HepaGam B from Apotex](#)
Pharma Live: Oct 23 2009 5:31AM Matching: cangene
- [Cangene acquires US commercialization rights for HepaGam B from Apotex](#)
PharmaBiz: Oct 22 2009 5:38AM Matching: cangene
- [Cangene acquires U.S. commercialization rights for HepaGam B from Apotex](#)
Bionity.com: Oct 22 2009 8:12AM Matching: cangene
- [Cangene Corporation announces financial results for the fiscal year ended July 31, 2009](#)
News-Medical.Net: Oct 22 2009 5:48AM Matching: cangene
- [Bay Street Stocks Finish Strong Thursday - Canadian Commentary](#)
RTTNews.com: Oct 22 2009 9:09PM Matching: cangene
- [Cangene announces highest-ever financial results for fiscal 2009 with net income up 102% to \\$59.9 million or 86 cents per share](#)
Individual.com: Oct 22 2009 1:30AM Matching: cangene
- [Cangene Corporation \(CC:CNJ\) Acquires U.S. Commercialization Rights for HepaGam B\(R\) from Apotex Corp. \(JOBS\):](#)
BioSpace: Oct 21 2009 3:26AM Matching: cangene
- [Cangene to host fiscal 2009 conference call on Thursday October 22, 2009 at 11:00 a.m. Eastern time](#)
Therapeutics Daily: Oct 21 2009 1:41AM Matching: cangene
- [Cangene to acquire U.S. commercialization rights for HepaGam B](#)
News-Medical.Net: Oct 20 2009 8:45AM Matching: cangene
- [Cangene signs agreement with Apotex Group to acquire U.S. commercialization rights for HepaGam B](#)
News-Medical.Net: Oct 20 2009 4:17AM Matching: cangene
- [Cangene to host fiscal 2009 conference call on Thursday October 22, 2009 at 11:00 a.m. Eastern time](#)
Individual.com: Oct 20 2009 7:27PM Matching: cangene
- [Cangene to host fiscal 2009 conference call on Thursday October 22, 2009 at 11:00 a.m. Eastern time](#)
CNW Telbec: Oct 20 2009 9:39PM Matching: cangene

- [Cangene acquires U.S. commercialization rights for HepaGam B\(R\) from Apotex](#)
CNW Telbec: Oct 19 2009 10:56PM Matching: cangene
- [Plasma firm transfers operations, prepares for electronic system](#)
SmartBrief: Oct 5 2009 7:22PM Matching: cangene
- [Canadian pharma seeks H1N1 flu victims for research](#)
Ottawa Citizen: Oct 2 2009 8:59AM Matching: cangene

Cangene Corporation Clinical Trials:



- [Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle](#)

Cangene Corporation Patents:



- 6271344- [Enhanced affinity hyaluronan binding peptides](#)
- 5200327- [Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor \(GM-CSF\) and other heterologous proteins from streptomyces](#)
- 5409818- [Nucleic acid amplification process](#)
- 5514590- [Expression system comprising DNA encoding the signal peptide of protease B from Streptomyces griseus](#)
- 5616485- [Streptomyces proteases and improved streptomyces strains for expression of peptides and polypeptides](#)
- 5641663- [Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor \(GM-CSF\) and other heterologous proteins from streptomyces](#)
- 5856166- [Streptomyces proteases and methods for improved secretion of recombinantly-expressed proteins](#)
- 5888774- [Recombinant DNA molecules and expression vectors for erythropoietin](#)
- 5985607- [Recombinant DNA molecules and expression vectors for tissue plasminogen activator](#)
- 5993812- [Method of delaying the progression of an infection with the human immunodeficiency virus](#)
- 6127144- [Method for expression of proteins in bacterial host cells](#)
- 5130238- [Enhanced nucleic acid amplification process](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to

your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

